<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Syphilis in Pregnancy &amp; Congenital Syphilis </h1><p><strong>(BASHH 2024)</strong></p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>1  Key epidemiology &amp; pathophysiology</strong></h3><p>• <em>T. pallidum</em> crosses the placenta at <strong>any stage of pregnancy</strong>; transmission risk peaks in early maternal infection and with RPR ≥ 1:8 (risk ratio 18) fileciteturn6file5.</p><p> • UK antenatal screening (∼700 000 per year) detects ≈ 400 cases needing treatment; congenital cases increasingly in UK‑born mothers fileciteturn6file5.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>2  Screening &amp; public‑health framework</strong></h3><table><tr><td><p><strong>When</strong></p></td><td><p><strong>What to do</strong></p></td><td><p><strong>Key points</strong></p></td></tr><tr><td><p><strong>Booking (first contact)</strong></p></td><td><p>Offer IDPS syphilis screen to <strong>every pregnancy</strong></p></td><td><p>Explain purpose; take sample immediately fileciteturn6file17</p></td></tr><tr><td><p><strong>Late presenters / in labour</strong></p></td><td><p>Urgent screen via UKAS lab</p></td><td><p>Liaise directly with lab for rapid analysis fileciteturn6file17</p></td></tr><tr><td><p><strong>Decliners</strong></p></td><td><p>Formal re‑offer within IDPS timeframes</p></td><td></td></tr><tr><td><p><strong>Triggers for re‑test</strong></p></td><td><p>New partner, STI in patient/partner, sex work, IVDU, symptoms</p></td><td><p>Re‑test at risk or ≥3 mo after last negative fileciteturn6file17</p></td></tr><tr><td><p><strong>Screen +/confirm– discordance</strong></p></td><td><p>Repeat sample 2 wk to exclude early infection</p></td><td></td></tr></table><h3 class="text-lg font-semibold mt-6 mb-3"><strong>3  Maternal assessment &amp; staging</strong></h3><p>• Positive treponemal screen = infected <strong>unless</strong> documented adequate prior treatment &amp; serological cure fileciteturn6file9.</p><p> • Stage as <em>early</em> (&lt;2 y) if clinical lesions or documented negative serology within 2 y; otherwise assume <em>late</em>.</p><p> • Rapid referral to named GUM clinician; late booking (&gt;20 wk) cases prioritised fileciteturn6file9.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4  Treatment principles (mother)</strong></h3><table><tr><td><p><strong>Maternal stage</strong></p></td><td><p><strong>Regimen</strong></p></td><td><p><strong>Pregnancy‑specific adaptations</strong></p></td></tr><tr><td><p><strong>Early syphilis</strong></p></td><td><p><strong>BPG 2.4 MU IM ×1</strong></p></td><td><p>Add second 2.4 MU dose 7 days later if (i) treatment given in 3rd trimester or (ii) fetal US suggests infection/placentomegaly fileciteturn6file0turn6file8</p></td></tr><tr><td><p><strong>Late latent / unknown duration</strong></p></td><td><p>BPG 2.4 MU IM weekly ×3</p></td><td><p>Same as non‑pregnant</p></td></tr><tr><td><p><strong>Neurosyphilis</strong></p></td><td><p>Benzylpenicillin 1.8–2.4 g IV 6‑hourly 14 d </p><p>or Procaine Pen + Probenecid</p></td><td><p>Continuous CSF levels; restart if &gt;24 h gap </p></td></tr><tr><td><p><strong>Penicillin allergy</strong></p></td><td><p>1) Verify history; 84 % skin‑test negative  2) If confirmed: <strong>ceftriaxone</strong> acceptable, or penicillin <strong>desensitisation</strong> in centre with resus kit.</p></td><td><p>Avoid macrolides; soya/peanut allergy ➜ use procaine pen or ceftriaxone fileciteturn6file7</p></td></tr></table><p><strong>Jarisch–Herxheimer in pregnancy</strong></p><p> • Occurs ≈40 %; may cause uterine contractions &amp; transient FH changes; generally self‑limiting fileciteturn6file7.</p><p> • Management = supportive (antipyretics, fluids); <strong>steroids NOT recommended</strong> for prevention fileciteturn6file2.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>5  Maternal follow‑up &amp; birth planning</strong></h3><p>• Serology: RPR at 3, 6, 12 mo; may be serofast or deliver before 4‑fold fall; repeat more often if reinfection risk fileciteturn6file1.</p><p> • Consider RPR at delivery to detect reinfection fileciteturn6file2.</p><p> • Create <strong>Syphilis Birth Plan</strong> with MDT (screening midwife, GUM, obstetrics, paediatrics, microbiology) and neonatal alert fileciteturn6file6.</p><p> • If treatment completed <strong>&lt;4 wk before delivery</strong> or non‑beta‑lactam/ incomplete, classify infant <em>high risk</em> and pre‑plan neonatal therapy fileciteturn6file2.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6  Neonatal risk stratification &amp; work‑up</strong></h3><table><tr><td><p><strong>Risk group</strong></p></td><td><p><strong>Maternal criteria</strong></p></td><td><p><strong>Neonatal actions</strong></p></td></tr><tr><td><p><strong>No risk</strong></p></td><td><p>Adequately treated <em>before</em> pregnancy, no reinfection</p></td><td><p>No tests fileciteturn6file6</p></td></tr><tr><td><p><strong>Low risk</strong></p></td><td><p>Correct penicillin/ceftriaxone regimen &gt;4 wk pre‑delivery, RPR falling, no relapse</p></td><td><p>Infant &amp; maternal serology at birth; repeat RPR/IgM at 3 mo; discharge if RPR‑/IgM‑ fileciteturn6file6</p></td></tr><tr><td><p><strong>High risk</strong></p></td><td><p><strong>Treatment &lt;4 wk, non‑beta‑lactam,</strong> incomplete/uncertain, or early untreated</p></td><td><p>Full exam, infant serology, <strong>CSF (cells, protein, RPR)</strong>, FBC, LFT, long‑bone X‑ray, direct PCR/dark‑ground if lesions fileciteturn6file6turn6file13</p></td></tr></table><p>### 7  Neonatal treatment (congenital or high‑risk)</p><table><tr><td><p><strong>Drug</strong></p></td><td><p><strong>Dose &amp; duration</strong></p></td><td><p><strong>Notes</strong></p></td></tr><tr><td><p><strong>Benzylpenicillin</strong></p></td><td><p>25 mg/kg IV q12 h (age ≤7 d); q8 h (7–28 d); q6 h (&gt;28 d) for <strong>10 d</strong></p></td><td><p>Max single dose 2.4 g; restart course if &gt;24 h gap fileciteturn6file13</p></td></tr><tr><td><p><strong>Ceftriaxone</strong></p></td><td><p>&lt;1 yr 75 mg/kg IV OD; ≥1 yr 100 mg/kg IV OD 10–14 d</p></td><td><p>Ambulatory option when admission impossible fileciteturn6file13</p></td></tr></table><p>### 8  Infant follow‑up &amp; special scenarios</p><p> • Infants treated at birth: RPR at 3, 6, 12 mo; discharge when ≥4‑fold fall or negative fileciteturn6file13.</p><p> • Persisting/ rising RPR or positive IgM → investigate for neurosyphilis (repeat LP) and retreat fileciteturn6file13.</p><p> • Notify <strong>ISOSS</strong> of all positive antenatal screens &amp; congenital cases fileciteturn6file13.</p><p> • Breastfeeding permitted unless active breast lesions present.</p><p>### 9  High‑yield exam flash points</p><p> • <strong>Double‑dose BPG</strong> needed if early syphilis treated in 3rd trimester or ultrasound signs.</p><p> • Jarisch–Herxheimer: supportive only; fetal monitoring advised; steroids not evidence‑based.</p><p> • Maternal treatment &lt;4 wk pre‑delivery = automatic neonatal therapy.</p><p> • Ceftriaxone is the <strong>preferred non‑penicillin</strong> alternative in pregnancy; macrolides contraindicated.</p><p> • Penicillin skin testing safe in pregnancy; 84 % test negative.</p><p> • Infant ‘no risk’ group needs <strong>no tests</strong> – common viva trap.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>10  Clinical features of congenital syphilis</strong></h3><p><strong>Early congenital (birth – 2 y)</strong> – signs usually emerge in the first 3 months, though many infants are asymptomatic at birth.</p><p>• Stillbirth, prematurity, low birth weight, neonatal death (<a href="https://www.cdc.gov/syphilis/about/about-congenital-syphilis.html">cdc.gov</a>)</p><p> • “Snuffles” (profuse mucopurulent nasal discharge), vesiculobullous or copper‑coloured macular rash on palms/soles, desquamating perioral/genital lesions (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • Hepatosplenomegaly, jaundice, generalized lymphadenopathy, severe anaemia and thrombocytopenia (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • Skeletal disease: osteochondritis and periostitis causing metaphyseal lucencies, Wimberger sign and <strong>pseudoparalysis of Parrot</strong> (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • CNS involvement – meningitis, hydrocephalus, seizures; eye involvement (chorioretinitis) (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p><strong>Late congenital (&gt; 2 y)</strong> – due to chronic inflammation/scarring.</p><p>• <strong>Hutchinson triad</strong>: interstitial keratitis, sensorineural deafness, Hutchinson (notched) incisors (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • Mulberry molars, high‑arched palate, “bulldog” facies / maxillary hypoplasia (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • Saddle‑nose deformity, frontal bossing; periosteal thickening giving <strong>saber shins</strong> (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p> • <strong>Clutton joints</strong> – painless symmetrical knee effusions (classically knees, age 6–16 y) (<a href="https://www.britannica.com/science/Clutton-joint">britannica.com</a>)</p><p> • Gummatous skin/bone lesions, palatal destruction, juvenile paresis, tabes dorsalis, optic atrophy (<a href="https://www.msdmanuals.com/professional/pediatrics/infections-in-neonates/congenital-syphilis">msdmanuals.com</a>)</p><p>These features are classic viva territory – remembering snuffles, pseudoparalysis, Hutchinson triad and Clutton joints often secures bonus marks.</p>
</div>